White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
BOJ Signals Faster Rate Hikes as Inflation Risks Raise September Move Odds 
US Dollar Near Two-Month Low as Markets Await Inflation Data 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
S&P 500, Nasdaq Futures Rise as Iran Risks and CPI Loom 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
England Drought Expands to 71% as Heatwave Deepens Water Crisis 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Japan Executives Warn Weak Yen and Currency Volatility Threaten Economy 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
Drugmakers including Pfizer Inc, GlaxoSmithKline PLC , Bristol Myers Squibb, AstraZeneca PLC and Sanofi SA will raise prices in the US on over 350 unique drugs in early January.
The increases are in preparation for the Inflation Reduction Act (IRA), which allows the government's Medicare health program to negotiate prices for some drugs starting in 2026.
The pharmaceutical industry is also dealing with inflation and supply chain constraints that increased manufacturing costs.
The price hikes are based on list prices, which do not account for other discounts or rebates to pharmacy benefit managers.
According to data released by 46brooklyn, a drug pricing non-profit affiliated with 3 Axis, drugmakers increased prices on more than 1,400 pharmaceuticals in 2022. Since 2015, there have been the most rises.
According to Antonio Ciaccia, president of 3 Axis, drugmakers have concentrated on releasing their medications at higher prices due to the concentration on annual price hikes.
More drug prices are likely to be announced over the course of January - historically the biggest month for drugmakers to raise prices.
Pfizer has so far disclosed the biggest price hikes, with 89 different prescription names seeing a rise in price in addition to an extra 10 drug brands at its Hospira division.
Then came GSK, which has already announced hikes for 26 different medications, including nearly a 7% rise for its well-known shingles vaccine Shingrix.
